April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Antimicrobial Peptides and Acanthamoeba: Peptide expression and anti-amoebicidal activity via time-lapse imaging
Author Affiliations & Notes
  • Joseph C Manarang
    College of Optometry, University of Houston, Houston, TX
  • Hasna Baidouri
    College of Optometry, University of Houston, Houston, TX
  • Satya Sree N Kolar
    College of Optometry, University of Houston, Houston, TX
  • Maria L Mangoni
    Sapienza University of Rome, Rome, Italy
  • Alison M McDermott
    College of Optometry, University of Houston, Houston, TX
  • Footnotes
    Commercial Relationships Joseph Manarang, None; Hasna Baidouri, None; Satya Sree Kolar, None; Maria Mangoni, None; Alison McDermott, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6266. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joseph C Manarang, Hasna Baidouri, Satya Sree N Kolar, Maria L Mangoni, Alison M McDermott; Antimicrobial Peptides and Acanthamoeba: Peptide expression and anti-amoebicidal activity via time-lapse imaging. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6266.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine human corneal epithelial cell antimicrobial peptide (AMP) expression in response to Acanthamoeba castellani (A. castellani) and to visualize the trophocidal activity of AMPs using time-lapse live cell imaging.

Methods: Telomerase modified human corneal epithelial cells (hTCEpi) were exposed to 2X105/ml A. castellani trophozoites for up to 24 hours and AMP (cathelicidin LL-37, human beta defensins (hBD) -1, -2, -3 and -4) mRNA expression determined by RT-PCR. AMP expression by A. castellani trophozoites was also investigated. For visualization of trophocidal activity, 1X105/ml A. castellani trophozoites stained with Ethidium homodimer-1 were exposed to 1-500 μg/ml of AMPs (LL-37, hBD-1, -2, -3, insect AMP Cecropin B and amphibian AMPs Magainin II and Esculentin1-21). Serial bright field and fluorescence images were taken every 3 minutes for 6 hours using a Deltavision Deconvolution microscope.

Results: As expected human AMPs were not expressed by A. castellani. hTCEpi exhibited low to no expression of hBD-2, -3, -4, and low to moderate expression of hBD-1 and LL-37 (n=3) under basal conditions. Exposure of hTCEpi to A. castellani trophozoites upregulated expression of hBD-1 5-fold and downregulated LL-37 by approximately 50% (n=2). Live cell imaging showed that LL-37 and hBD-1 were not amoebecidal even at 200μg/ml, the highest concentration tested. hBD-2 caused some trophozoite rupture with deposition of cellular debris at 200μg/ml, although multiple viable and dividing trophozoites were still observed. hBD-3 resulted in minimal cellular debris deposition at 100μg/ml. Esculentin1-21 exhibited complete trophocidal activity at 250μg/ml. Cecropin B exhibited partial trophocidal activity at 500μg/ml, whereas Magainin II exhibited complete killing at 500μg/ml, with no deposition of cellular debris in the background.

Conclusions: hBD-1 was upregulated in corneal epithelial cells, whereas LL-37 was downregulated. Though hBD-1 expression was increased, this and the other human AMPs showed minimal activity against A. castellani at the concentrations tested. The non-human AMPs Esculentin1-21, Cecropin B, and Magainin II exhibited potent amoebicidal activity at higher concentrations. These findings suggest that some AMPs have the potential to serve as amoebicidal agents for acanthamoeba keratitis and as disinfectants in contact lens care solutions.

Keywords: 402 Acanthamoeba • 482 cornea: epithelium • 422 antibiotics/antifungals/antiparasitics  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×